ArticleNature2022
Single-cell genomic variation induced by mutational processes in cancer.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
14.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 144 citations in OpenAlex.
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer.Molecular oncology · 2026Article
- Therapy-Related Mutational Signatures in Subsequent Neoplasms among Survivors of Childhood Cancer.Cancer discovery · 2026Article
- CNVeil resolves haplotype-specific copy number and uncovers subclonal architecture hidden from total copy number profiling in single-cell cancer genomes.bioRxiv : the preprint server for biology · 2026Article
- LeafRank: A phylodynamic framework for inferring relative fitness from single-cell phylogenies in chromosomally unstable tumors.bioRxiv : the preprint server for biology · 2026Article
- Long-read sequencing of single cell-derived melanoma sublines reveals divergent and parallel genomic and epigenomic evolutionary trajectories.Nature communications · 2026Article
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.Cancer science · 2026Article
- Evolution of oncogene amplification across 86,000 cancer cell genomes.bioRxiv : the preprint server for biology · 2026Article
- Tissue-Specific Prevalence and Clonal Architecture ofbioRxiv : the preprint server for biology · 2026Article
- Spatial tumor evolution panorama of ovarian cancer.Cell reports. Medicine · 2026Article
- Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis.EBioMedicine · 2026Article
- It's a kind of MAGIC: uncovering the origins of chromosomal instability.Signal transduction and targeted therapy · 2026Article
- Genomic evolution of pancreatic cancer at single-cell resolution.Nature genetics · 2026Article
- Mutational Landscape Analysis of BRCA1/2 and Identification of Extracellular-Vesicle-Related Biomarkers in Triple-Negative Breast Cancer.Biomedicines · 2026Article
- SVCROWS: a user-defined tool for interpreting significant structural variants in heterogeneous datasets.Nucleic acids research · 2026Article
- Theoretical estimates on the expected number of mutations needed to reconstruct clonal lineage trees.Bioinformatics advances · 2026Article
- Single-cell aneuploidy and chromosomal arm imbalances define subclones with divergent transcriptomic phenotypes.NAR genomics and bioinformatics · 2025Article
- Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study.Journal of translational medicine · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors at 10 institutions in 4 countries.
Tyler Funnell *Tri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-1612-5644
Ciara H O'Flanagan *Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Marc J Williams *Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. william1@mskcc.org.ORCID http://orcid.org/0000-0001-5524-4174
Andrew McPhersonComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Steven McKinneyDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-1611-0867
Farhia KabeerDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Hakwoo LeeDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Sohrab SalehiComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ignacio Vázquez-GarcíaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hongyu ShiComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emily LeventhalComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tehmina MasudDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Peter EirewDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Damian YapDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-5370-4592
Allen W ZhangDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Jamie L P LimComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Beixi WangDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Jazmine BrimhallDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Justina BieleDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Jerome TingDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Vinci AuDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-3587-6200
Michael Van VlietDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Yi Fei LiuDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Sean BeattyDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0001-6819-7071
Daniel LaiDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0001-9203-6323
Jenifer PhamDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Diljot GrewalComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Douglas AbramsComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eliyahu HavasovComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Samantha LeungComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Viktoria BojilovaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richard A MooreMichael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Nicole RuskComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2663-6288
Florian UhlitzComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicholas CegliaComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adam C WeinerTri-Institutional PhD Program in Computational Biology and Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-5968-3606
Elena ZaikovaDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
J Maxwell DouglasDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Dmitriy ZamarinGYN Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0094-0161
Britta WeigeltDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9927-1270
Sarah H KimDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Arnaud Da Cruz PaulaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2969-3173
Spencer D MartinDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Yangguang LiDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Hong XuDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Teresa Ruiz de AlgaraDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
So Ra LeeDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Viviana Cerda LlanosDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
David G HuntsmanDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Jessica N McAlpineDepartment of Gynecology and Obstetrics, University of British Columbia, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0001-6003-485X
IMAXT Consortium
Sohrab P ShahComputational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahs3@mskcc.org.ORCID http://orcid.org/0000-0001-6402-523X
Samuel AparicioDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada. saparicio@bccrc.ca.ORCID http://orcid.org/0000-0002-0487-9599
University of Cambridge · GBMemorial Sloan Kettering Cancer Center · USMcGovern Institute for Brain Research · USUniversity of British Columbia · CAHoward Hughes Medical Institute · USUniversity of Zurich · CHLudwig Cancer Research · USLudwig Cancer Research · CHBC Cancer Agency · CACanada's Michael Smith Genome Sciences Centre · CA
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MCenter for Integrated Cellular Analysis - Valeria A. Sanchez EstradaRM1HG011014 · NHGRI · NEW YORK GENOME CENTER · PI LANDAU, DAN, SATIJA, RAHUL · 2020 to 2025
$22.1MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3MSingle cell quantification of genomic instability in cancer as a determinant of therapeutic responseK99CA256508 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI WILLIAMS, MARC · 2021 to 2022
$200kCancer Research UKNCI NIH HHS K99 CA256508NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NHGRI NIH HHS RM1 HG011014
Abstract
How cell-to-cell copy number alterations that underpin genomic instability
Indexed as
GenomicsMutationOvarian NeoplasmsSingle-Cell AnalysisTriple Negative Breast NeoplasmsBRCA1 ProteinBRCA2 ProteinFemaleHumansPhylogenyTumor Suppressor Protein p53BRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.